Pam2csk4
Also known as: Dipalmitoyl-CSK4, Pam2CSK4, S-[2,3-Bis(palmitoyloxy)propyl]cysteine-serine-(lysine)4, TLR2/6 agonist lipopeptide
Source Pam2csk4 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pam2CSK4 (also called Dipalmitoyl‑CSK4) is a synthetic di‑acylated lipopeptide that selectively activates the Toll‑like receptor 2/6 (TLR2/6) heterodimer. In research it is employed as an immune‑stimulating agent and vaccine adjuvant, administered by routes such as intranasal, intraperitoneal, subcutaneous or topical application. Studies show it can boost antibody production, promote Th1‑type cellular responses, and influence epithelial and dendritic cell signaling pathways.
Mechanism of Action
Pam2CSK4 binds the extracellular domain of the TLR2/6 heterodimer, recruiting the adaptor MyD88 and triggering downstream IRAK‑4/1 and TRAF6 signaling. This cascade activates NF‑κB and MAPK pathways, leading to transcription of pro‑inflammatory cytokines (e.g., IL‑1β, TNF‑α) and chemokines. In intestinal epithelium, Pam2CSK4‑induced TLR2 signaling can stimulate secretion of the serine protease inhibitor SPINK4, which in turn engages EGFR‑driven Wnt/β‑catenin and Hippo pathways to promote goblet‑cell differentiation.
What the Research Shows
Pre‑clinical work demonstrates that Pam2CSK4 robustly activates human peripheral blood mononuclear cells, increasing IL‑1β release and NF‑κB activation, effects that can be blocked by colchicine. In dendritic‑cell cultures, the peptide drives maturation unless counter‑acted by seminal plasma, which imposes a tolerogenic phenotype. In skin keratinocytes, Pam2CSK4 stimulates NOD2‑related antimicrobial peptide expression, implicating it in hidradenitis suppurativa pathology. In mouse models of colitis, Pam2CSK4 triggers SPINK4 production, aiding goblet‑cell recovery and synergising with anti‑TNF therapy. As a vaccine adjuvant, Pam2CSK4 enhances SARS‑CoV‑2 receptor‑binding‑domain nanoparticle immunogenicity, raising neutralising antibody titres, Th1 bias, and memory T‑cell formation. In ducks, Pam2CSK4 alone shows limited adjuvant effect, but combined with poly(I:C) and imiquimod it markedly improves H9N2 influenza vaccine responses.
Reported Benefits
Evidence from animal and cell studies suggests Pam2CSK4 can amplify both humoral and cellular immunity, making it a potent adjuvant for subunit vaccines such as SARS‑CoV‑2 RBD nanoparticles. It promotes Th1‑type cytokine profiles and memory T‑cell differentiation, potentially improving vaccine durability. In intestinal research, Pam2CSK4‑induced SPINK4 production supports goblet‑cell regeneration and may aid mucosal healing in colitis models. Its ability to activate innate pathways also provides a tool for dissecting TLR2/6‑mediated immune mechanisms.
Limitations of the Evidence
All data are pre‑clinical; no human clinical trials have evaluated safety or efficacy. The immunostimulatory effect can be context‑dependent—seminal plasma suppresses Pam2CSK4‑driven dendritic‑cell activation, and in ducks Pam2CSK4 alone fails to boost influenza vaccine responses. Its pro‑inflammatory activity (e.g., IL‑1β induction) may exacerbate conditions like Familial Mediterranean Fever, indicating a risk of unwanted inflammation. Consequently, translation to therapeutic use remains uncertain.
Safety Considerations
No human safety data are available. In vitro, Pam2CSK4 stimulates cytokine release (IL‑1β, TNF‑α) and NF‑κB activation, suggesting a potential for acute inflammatory reactions. Animal studies report no overt toxicity but focus on immunologic outcomes. Colchicine can inhibit Pam2CSK4‑mediated signaling, highlighting possible drug‑interaction considerations. Caution is warranted until formal toxicology and dose‑range studies are performed.
How It Is Administered
Research protocols employ Pam2CSK4 via intranasal, intraperitoneal, subcutaneous injection or topical application, typically dissolved in aqueous or lipid‑based carriers appropriate for the experimental model. Formulations are synthetic lipopeptide solutions or incorporated into nanoparticle vaccine platforms.
Routes of Administration
Goals & Uses
- Vaccine adjuvantVaccinologyModerate
- Mucosal immunity inductionImmunologyModerate
- TLR2/TLR6 pathway research toolBasic ResearchHigh
- Anti-infective prophylaxis (research)Infectious DiseaseLow
- Innate immune activationImmunostimulationHigh
- Innate immunity researchResearch ToolHigh
- TLR2 activationImmunostimulationHigh
Contraindications
- Systemic administration in inflammatory conditionsClinicalHigh
- Autoimmune diseaseImmuneModerateMay worsen or interact with immune-mediated disease
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Human therapeutic useRegulatory/safetyHigh
Adverse Effects
- Sepsis-like syndrome (high dose)Systemic ToxicityRare
- Pro-inflammatory cytokine release (TNF-α, IL-6, IL-12)Systemic Immune ReactionCommon
- Fever / pyrogenicitySystemic Immune ReactionUncommon
- Local inflammationLocalCommonInflammatory response at or near the administration site
- Local inflammation at injection siteLocal ReactionCommon
- Systemic cytokine releaseSystemicUncommon
Drug Interactions
- Immunosuppressants (e.g., corticosteroids, tacrolimus)Moderate
- Other TLR agonistsModerate
- ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
Population Constraints
- ElderlyAgeRelative
- Immunocompromised animals/modelsPreclinicalRelative
- ChildrenPediatricRelative
- Human subjectsRegulatory/SafetyAbsolute
Regulatory Status
- European UnionUnapprovedNot authorized for clinical use
- United StatesUnapprovedInvestigational reagent only
- United KingdomUnapprovedResearch grade only
No regulatory approval; classified as a research reagent. Not intended for human administration outside of controlled clinical trials.
Evidence & Sources
- Journal ArticleModerateRemes Lenicov F, et al.2012-01-01T00:00:00.000000Z
- Journal ArticleModerateBen-David H, et al.2018-01-01T00:00:00.000000Z
- Journal ArticleLowGambichler T, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleLowWang Y, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleLowQiao Y, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleLowZhang A, et al.2022-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of immune response does Pam2CSK4 promote?
Pam2CSK4 activates TLR2/6, leading to MyD88‑dependent NF‑κB signaling that drives pro‑inflammatory cytokine release and a Th1‑biased cellular response, while also enhancing antibody production when used as a vaccine adjuvant.
Has Pam2CSK4 been tested in humans?
All published data are from cell cultures or animal models. No human clinical trials or regulatory approvals have been reported for Pam2CSK4.
Can Pam2CSK4 cause harmful inflammation?
In vitro studies show it induces cytokines such as IL‑1β and TNF‑α, which could provoke inflammation. The extent of any adverse effect in vivo is unknown and requires formal safety evaluation.
Why did Pam2CSK4 not improve duck influenza vaccine responses alone?
The study found that Pam2CSK4 by itself did not significantly raise Th1 cytokines or antibody titres in ducks, but when combined with poly(I:C) and imiquimod it produced a synergistic adjuvant effect, indicating species‑specific or context‑dependent activity.
How does Pam2CSK4 influence gut health in colitis models?
Pam2CSK4 stimulates the production of the protease inhibitor SPINK4, which promotes goblet‑cell differentiation via EGFR‑Wnt/β‑catenin and Hippo pathways, helping restore mucus barrier function and synergising with anti‑TNF therapy in mouse colitis.
What is Pam2csk4?
Pam2CSK4 (also called Dipalmitoyl‑CSK4) is a synthetic di‑acylated lipopeptide that selectively activates the Toll‑like receptor 2/6 (TLR2/6) heterodimer. In research it is employed as an immune‑stimulating agent and vaccine adjuvant, administered by routes such as intranasal, intraperitoneal, subcutaneous or topical application. Studies show it can boost antibody production, promote Th1‑type cellular responses, and influence epithelial and dendritic cell signaling pathways.
What is Pam2csk4 used for?
Pam2csk4 is educationally associated with: Vaccine adjuvant, Mucosal immunity induction, TLR2/TLR6 pathway research tool, Anti-infective prophylaxis (research), Innate immune activation, Innate immunity research, TLR2 activation. Educational only — not medical advice.
How is Pam2csk4 administered?
Recorded routes of administration: In Vitro, Intradermal, Intramuscular, Intranasal, Intraperitoneal, Intravenous, Subcutaneous, Topical.
What are the potential side effects of Pam2csk4?
Reported adverse effects include: Sepsis-like syndrome (high dose), Pro-inflammatory cytokine release (TNF-α, IL-6, IL-12), Fever / pyrogenicity, Local inflammation, Local inflammation at injection site, Systemic cytokine release. This list is not exhaustive — consult a qualified clinician.
Who should avoid Pam2csk4?
Recorded contraindications: Systemic administration in inflammatory conditions, Autoimmune disease, Pregnancy, Human therapeutic use. Consult a qualified clinician before use.